4//SEC Filing
Wooldridge James 4
Accession 0000899243-22-020081
CIK 0001651431other
Filed
May 30, 8:00 PM ET
Accepted
May 31, 10:04 AM ET
Size
15.6 KB
Accession
0000899243-22-020081
Insider Transaction Report
Form 4
Wooldridge James
Chief Medical Officer
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2022-05-31−101,180→ 0 totalExercise: $2.05Exp: 2032-01-26→ Common Stock (101,180 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2022-05-31−54,600→ 0 totalExercise: $13.50Exp: 2031-03-03→ Common Stock (54,600 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2022-05-31−27,300→ 0 totalExercise: $5.09Exp: 2031-08-03→ Common Stock (27,300 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2022-05-31−150,818→ 0 totalExercise: $15.00Exp: 2030-08-05→ Common Stock (150,818 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2022-05-31−95,916→ 0 totalExercise: $2.62Exp: 2029-09-05→ Common Stock (95,916 underlying)
Footnotes (2)
- [F1]At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the "Issuer"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the "Merger"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an "In the Money Issuer Option") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes.
- [F2]At the effective time of the Merger, each option granted by the Issuer to purchase Issuer Common Stock which has a per share exercise price greater than or equal to $10.50 that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled with no consideration payable.
Documents
Issuer
Checkmate Pharmaceuticals, Inc.
CIK 0001651431
Entity typeother
Related Parties
1- filerCIK 0001710641
Filing Metadata
- Form type
- 4
- Filed
- May 30, 8:00 PM ET
- Accepted
- May 31, 10:04 AM ET
- Size
- 15.6 KB